WO2011093809A2 - Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide - Google Patents

Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide Download PDF

Info

Publication number
WO2011093809A2
WO2011093809A2 PCT/TR2011/000011 TR2011000011W WO2011093809A2 WO 2011093809 A2 WO2011093809 A2 WO 2011093809A2 TR 2011000011 W TR2011000011 W TR 2011000011W WO 2011093809 A2 WO2011093809 A2 WO 2011093809A2
Authority
WO
WIPO (PCT)
Prior art keywords
dry powder
capsule
particle size
mean particle
powder form
Prior art date
Application number
PCT/TR2011/000011
Other languages
English (en)
Other versions
WO2011093809A3 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00620A external-priority patent/TR201000620A2/xx
Priority claimed from TR2010/00729A external-priority patent/TR201000729A2/xx
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093809A2 publication Critical patent/WO2011093809A2/fr
Publication of WO2011093809A3 publication Critical patent/WO2011093809A3/fr
Priority to US13/531,972 priority Critical patent/US8834931B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • lactose which has a mean particle size less than 100 ⁇ is used as carrier.
  • said active agents are present in the composition with the ratio of 1:3 to 1:40 respectively and
  • said active agents are present in the composition with the ratio of 1:3 to 1:40 respectively and
  • ⁇ lactose which has a mean particle size less than 100 ⁇ is used as carrier as stored together in a peelable blister or pierceable capsule pack in the treatment of respiratory diseases such as asthma and COPD.
  • the capsule or the blister pack which comprises the formulation pertaining to the present invention, can be used with any dry powder inhalation device, for example with devices as described in the patent applications numbered TR2008/03522, TR2008/03523, TR2010/03091, TR2010/04311.
  • the thickness of the aluminum foil that is used in the lid and the base sheets of the blister pack is chosen to be in the range of 10 to 40 ⁇ , preferably of 15 to 30 ⁇ .
  • the polymeric layers in the lid and the base sheets of the blister pack mentioned in the present invention are composed of the same or different polymers. The thickness of these polymeric layers varies according to the type of the polymeric substance used and its properties. Therefore, the thickness of the polymeric layer varies in the range of 15-60 ⁇ , preferably of 20-35 ⁇ depending on the type of the polymer used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques sous forme de poudre sèche comprenant du tiotropium et du ciclésonide et/ou leurs dérivés pharmaceutiquement acceptables utilisés comme principes actifs. Elle concerne également des formes en capsules ou plaquettes alvéolaires contenant ces compositions pharmaceutiques destinées à être utilisées dans le traitement de maladies des voies respiratoires.
PCT/TR2011/000011 2009-12-25 2011-01-28 Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide WO2011093809A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00620A TR201000620A2 (tr) 2010-01-28 2010-01-28 Tiotropium ve siklesonid içeren kuru toz formundaki farmasötik kompozisyon.
TR2010/00620 2010-01-28
TR2010/00729 2010-02-02
TR2010/00729A TR201000729A2 (tr) 2010-02-02 2010-02-02 Tiotropyum ve siklesonid içeren kuru toz formundaki farmasötik kompozisyon

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000012 Continuation-In-Part WO2011093810A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000251 Continuation-In-Part WO2011078824A1 (fr) 2009-12-25 2010-12-20 Formulation de poudre sèche contenant tiotropium et destinée à l'inhalation

Publications (2)

Publication Number Publication Date
WO2011093809A2 true WO2011093809A2 (fr) 2011-08-04
WO2011093809A3 WO2011093809A3 (fr) 2012-02-23

Family

ID=43928937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000011 WO2011093809A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide

Country Status (1)

Country Link
WO (1) WO2011093809A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418716A1 (fr) 1989-09-16 1991-03-27 Boehringer Ingelheim Kg Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires, leur préparation et l'utilisation de ces composés
US5482834A (en) 1982-05-17 1996-01-09 Hahnemann University Evaluation of nucleic acids in a biological sample hybridization in a solution of chaotrophic salt solubilized cells
TR200803523A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Şerit ambalaj içeren düzenek
TR200803522A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Kolay kullanımlı inhalasyon cihazı.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
EP1531866A1 (fr) * 2002-08-29 2005-05-25 Cipla Ltd. Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
AU2008217586A1 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
TR200909792A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482834A (en) 1982-05-17 1996-01-09 Hahnemann University Evaluation of nucleic acids in a biological sample hybridization in a solution of chaotrophic salt solubilized cells
EP0418716A1 (fr) 1989-09-16 1991-03-27 Boehringer Ingelheim Kg Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires, leur préparation et l'utilisation de ces composés
TR200803523A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Şerit ambalaj içeren düzenek
TR200803522A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Kolay kullanımlı inhalasyon cihazı.

Also Published As

Publication number Publication date
WO2011093809A3 (fr) 2012-02-23

Similar Documents

Publication Publication Date Title
EP2528585B1 (fr) Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide
EP2528600B1 (fr) Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone
EP2528596B1 (fr) Composition sous forme de poudre sèche pour administration par inhalation comprenant une combinaison de bromure de tiotropium, de xynafoate de salmeterol et de propionate de fluticasone.
EP2533777B1 (fr) Compositions pharmaceutiques contenant de la fluticasone, du tiotropium et du cromoglycate de sodium
WO2011093819A2 (fr) Nouvelle composition pharmaceutique combinée comprenant du tiotropium
WO2011093820A2 (fr) Composition pharmaceutique combinée comprenant du tiotropium
WO2011093815A2 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
WO2011093818A2 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
WO2011093811A2 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
EP2480203B1 (fr) Formulation de poudre sèche de tiotropium contenue dans une bande alvéolée thermoformée
WO2011093812A2 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
EP2528597B1 (fr) Composition sous form de poudre sèche comprenant une combinaison de bromure de tiotropium, fumarate de formoterol et de furoate de mometasone
WO2011093814A2 (fr) Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2013109219A1 (fr) Formulations en poudre sèche comprenant du tiotropium et du carmotérol
WO2011093810A2 (fr) Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone
EP2804585A1 (fr) Formulations en poudre sèche comprenant du tiotropium, du formotérol et du budésonide
WO2011093809A2 (fr) Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide
EP2515845B1 (fr) Formulation de poudre sèche comprenant du tiotropium, du formoterol et un derive d'acide cromoglicine
EP2515848A1 (fr) Combinaison de poudre sèche constituée de tiotropium, d'un corticostéroïde et d'un dérivé d'acide cromoglicique
WO2011049539A1 (fr) Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil
WO2011037551A2 (fr) Bande alvéolée thermoformée contenant une combinaison qui renferme du tiotropium
WO2013109218A1 (fr) Formulations en poudre sèche comprenant du carmotérol et de la ciclésonide
WO2011049538A2 (fr) Composition pharmaceutique sous forme de poudre sèche
EP2804589A1 (fr) Formulations pharmaceutiques comprenant de l'aztréonam
WO2013109207A1 (fr) Formulations de poudre sèche comprenant de la mométasone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11707504

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11707504

Country of ref document: EP

Kind code of ref document: A2